Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $51.70 Consensus Price Target from Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been given an average recommendation of “Buy” by the nine analysts that are presently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $51.70.

MIRM has been the subject of a number of recent analyst reports. JMP Securities upped their target price on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, March 14th. HC Wainwright reiterated a “buy” rating and set a $58.00 price objective on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 2nd. SVB Leerink dropped their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research report on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $35.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. Finally, Stifel Nicolaus initiated coverage on shares of Mirum Pharmaceuticals in a research note on Wednesday, April 17th. They issued a “buy” rating and a $48.00 price objective on the stock.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $25.04 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 4.19 and a current ratio of 4.45. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -6.31 and a beta of 1.13. Mirum Pharmaceuticals has a 52 week low of $23.14 and a 52 week high of $35.56. The firm’s 50-day simple moving average is $25.99 and its 200 day simple moving average is $28.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). The business had revenue of $69.55 million during the quarter, compared to analyst estimates of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. As a group, sell-side analysts predict that Mirum Pharmaceuticals will post -1.34 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt acquired 2,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 18th. The shares were acquired at an average price of $25.80 per share, for a total transaction of $51,600.00. Following the transaction, the chief financial officer now directly owns 12,000 shares of the company’s stock, valued at approximately $309,600. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, COO Peter Radovich sold 4,303 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the completion of the transaction, the chief operating officer now owns 29,013 shares of the company’s stock, valued at $748,535.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Eric Bjerkholt purchased 2,000 shares of the business’s stock in a transaction dated Monday, March 18th. The shares were acquired at an average price of $25.80 per share, for a total transaction of $51,600.00. Following the acquisition, the chief financial officer now owns 12,000 shares of the company’s stock, valued at approximately $309,600. The disclosure for this purchase can be found here. Company insiders own 22.87% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. William Blair Investment Management LLC grew its position in shares of Mirum Pharmaceuticals by 0.9% in the 1st quarter. William Blair Investment Management LLC now owns 627,272 shares of the company’s stock valued at $15,757,000 after buying an additional 5,494 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 11.7% in the first quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company’s stock worth $439,000 after acquiring an additional 1,825 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Mirum Pharmaceuticals by 7.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,641 shares of the company’s stock valued at $448,000 after acquiring an additional 1,246 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Mirum Pharmaceuticals by 66.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,952 shares of the company’s stock valued at $225,000 after purchasing an additional 3,558 shares during the period. Finally, Wetzel Investment Advisors Inc. raised its holdings in Mirum Pharmaceuticals by 71.4% during the 1st quarter. Wetzel Investment Advisors Inc. now owns 2,400 shares of the company’s stock worth $57,000 after purchasing an additional 1,000 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.